|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Revenue: | ||||
| Collaboration revenue | ||||
| Total revenue | ||||
| Cost of goods sold | ||||
| Cost of revenue: | ||||
| Cost of collaboration revenue | ||||
| Gross profit | ||||
| Operating expenses: | ||||
| Research and development | ||||
| General and administrative | ||||
| Total operating expenses | ||||
| Loss from operations | ||||
| Other income (expense), net | ||||
| Interest expense, net | ||||
| Interest expense | ||||
| Loss on conversion of notes | ||||
| Interest income | ||||
| Total other income (expense), net | ||||
| Net loss | ||||
| Deemed dividend related to warrant exercise price adjustment | ||||
| Net loss attributable to common stockholders | ||||
| Net loss per common share attributable to common stockholders - basic | ||||
| Net loss per common share attributable to common stockholders - diluted | ||||
| Weighted average number of shares outstanding - basic | ||||
| Weighted average number of shares outstanding - diluted | ||||
Loading...